A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment

Ninomiya, Hiroshi; Ozeki, Michio; Matsuzawa, Yoriko; Nozawa, Akifumi; Yasue, Shiho; Kubota, Keiichi; Endo, Saori; Asano, T.; Taguchi, Kohtaro; Ohe, Naoyuki; Iwama, Toru; Ohnishi, Hiroyuki

doi:10.1016/j.jocn.2020.10.009

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it was also reported that in cases with recurrent GBM, VEGF 121 protein plasma level was threefold higher than the levels of healthy volunteers, and that the mRNA isoform in their tumor tissue had a higher expression in patients with high level of plasma VEGF 121 (23). In children using bevacizumab in the treatment of gliomatosis cerebri, the plasma VEGF 121 level decreases (24). This decrease can be correlated with the decrease in tumor tissue and give an idea about the effi cacy of the treatment.…”

Section: Discussionmentioning

confidence: 97%

Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma

Tunçkale¹,

Çalışkan²,

Potoglu³

et al. 2023

BLL

View full text Add to dashboard Cite

OBJECTIVE: The aim of this study is to determine biomarkers, which may be used in order to understand the pathophysiology, the diagnosis, progression surveillance/monitoring, and treatment effi cacy of high graded glial tumors. BACKGROUND: Radiological imaging in the diagnosis and relapse surveillance of glial tumors is sometimes insuffi cient. There is need for additional methods of diagnosis and surveillance in order to rule out contradictory circumstances. METHOD: Using enzyme like immune sorbent assay method, E-Cadherin, Tenascin C, Tetraspanin 8, Survivin and VEGF121 levels were investigated in serum and tumor tissues of 28 patients diagnosed with pathological glioblastoma, and in the serum of 26 healthy individuals. Correlation between tumor tissue values and Ki67 percentage, and P53 mutation, and difference between unhealthy and healthy serum levels were sought. RESULTS: It was found out that E-Cadherin and VEGF 121 levels in the unhealthy serum were high in comparison to the control group (p < 0.05). In the patient group, there was no correlation determined between tissue and serum levels of all biomarkers and mutation percentages of Ki67 and p53 (p > 0.05). CONCLUSION: EC and VEGF121 are biomarkers, which have the potential to be used in the diagnosis, recurrence and treatment follow-up in high graded glial tumors (Tab. 2, Fig. 1, Ref. 37).

show abstract

Section: Discussionmentioning

confidence: 97%

Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma

Tunçkale¹,

Çalışkan²,

Potoglu³

et al. 2023

BLL

View full text Add to dashboard Cite

show abstract

A Synopsis of Biomarkers in Glioblastoma: Past and Present

Tataranu,

Turliuc,

Rizea

et al. 2024

CIMB

View full text Add to dashboard Cite

Accounting for 48% of malignant brain tumors in adults, glioblastoma has been of great interest in the last decades, especially in the biomolecular and neurosurgical fields, due to its incurable nature and notable neurological morbidity. The major advancements in neurosurgical technologies have positively influenced the extent of safe tumoral resection, while the latest progress in the biomolecular field of GBM has uncovered new potential therapeutical targets. Although GBM currently has no curative therapy, recent progress has been made in the management of this disease, both from surgical and molecular perspectives. The main current therapeutic approach is multimodal and consists of neurosurgical intervention, radiotherapy, and chemotherapy, mostly with temozolomide. Although most patients will develop treatment resistance and tumor recurrence after surgical removal, biomolecular advancements regarding GBM have contributed to a better understanding of this pathology and its therapeutic management. Over the past few decades, specific biomarkers have been discovered that have helped predict prognosis and treatment responses and contributed to improvements in survival rates.

show abstract

A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment

Cited by 2 publications

References 5 publications

Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma

Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma

A Synopsis of Biomarkers in Glioblastoma: Past and Present

Contact Info

Product

Resources

About